In vivo experiments showed that vandetanib can significantly reduce a number of typical asthma symptoms, such as loss of ciliated epithelium, airway inflammation and mucus hypersecretion, by reducing receptor tyrosine kinases and inflammatory factors. Here, NTRK1 is linked to asthma.